Heart Failure

The FDA has expanded the indication for the MitraClip to include heart failure patients with moderate-to-severe secondary mitral regurgitation, the agency announced March 14. Abbott’s transcatheter mitral valve repair device was approved in 2013, but only for primary mitral regurgitation.

The FDA fast-tracked the approval process for a new generic valsartan product (Diovan) amid an ongoing shortage of the blood pressure and heart failure medication.

A new stem cell-based test may add certainty to efforts to predict whether so-called variants of uncertain significance will contribute to the development of diseases or be harmless. 

Even though the Hospital Readmission Reduction Program (HRRP) targeted principal heart failure admissions, a new analysis in the Journal of the American College of Cardiology showed readmissions also declined for patients with a secondary diagnosis of heart failure.

By the time three transplant physicians approached Tom Giangiulio Jr. about being the first patient in a new clinical trial to accept a heart from a Hepatitis C-positive donor, Giangiulio didn’t have much of a choice.

One in six patients with heart failure with reduced ejection fraction (HFrEF) develops worsening HF within 18 months of an initial diagnosis, according to research published in the Journal of the American College of Cardiology, and these declining patients aren’t receiving the right standard of care.

Nearly half of patients with heart failure (HF) take at least 10 medications per day, according to research published in the American Journal of Cardiology, yet an overwhelming 85 percent report willingness to add more drugs to that regimen if it helps them prevent further health events.

A nurse navigator-led program at Providence St. Vincent Medical Center in Oregon helped the hospital double its palliative care referral rates for advanced heart failure patients considered to be at high risk of readmission.

Oregon Health & Sciences University might have a chance to revive the heart transplant program it shuttered last August after all four of its cardiologists left the institution, according to reports from the Oregonian and Oregon Live.

T2 mapping derived from weekly cardiac MRIs helped researchers identify cardiotoxicity at an early and reversible stage, a finding which may have implications for cancer patients at risk of chemotherapy-induced heart failure.

Heart failure (HF)—both symptomatic and asymptomatic—is associated with an up to 10 percent increased risk of 90-day postoperative mortality in patients undergoing noncardiac surgery, according to a study published Feb. 12 in the Journal of the American Medical Association.

His-optimized cardiac resynchronization therapy successfully narrowed QRS duration, improved left ventricular (LV) ejection fraction and heightened functionality in 27 patients with advanced heart failure (HF), according to a study published in Circulation: Arrhythmia and Electrophysiology.